Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Pancreatic cancer outcomes 'unimproved' in 40 years

  • Comment

Long-term survival among patients with pancreatic cancer has hardly improved in four decades, a charity has warned.

Just 3% of patients with the disease live for at least five years after diagnosis, Cancer Research UK said.

This is only a slight improvement from the 1970s when only 2% of patients survived for five years.

The majority of patients die within a year of diagnosis, the charity said.

“We’ve been waiting too long for new drugs to treat the disease and there are very few options available for people with advanced forms of the disease”

Andrew Biankin

Most cases of pancreatic cancer are not detected until it is too late and a lack of effective tests and treatments for the disease contributes to the poor survival rates.

It is the 10th most common cancer in the UK – every year around 8,800 people are diagnosed with the disease and around 8,300 die from it.

Over the next five years Cancer Research UK is planning to more than double the £6m it spends on research into the disease each year, a spokesman said.

Charity chief executive Harpal Kumar said: “It’s shocking that so many patients are still losing their lives to pancreatic cancer, which is why we’ve made it a priority to ignite a new wave of research that will see the disease detected earlier and much-needed treatments getting to patients sooner.

Harpal Kumar

Harpal Kumar

“Overall, more than half of all cancer patients now survive at least a decade, which is testament to the power of research to transform people’s lives,” he said.

“But disappointingly, we are nowhere near that level with pancreas cancer, and we won’t stop until we can bring those kinds of results to all patients, regardless of their cancer type.”

Professor Andrew Biankin, who works at Cancer Research UK’s Beatson Institute at the University of Glasgow, added: “Pancreatic cancer has very few symptoms at first and I see far too many patients who, out of the blue, are told they may have just months or even weeks to live.

“We’ve been waiting too long for new drugs to treat the disease and there are very few options available for people with advanced forms of the disease,” he said.

“It’s a situation that simply has to change and we can only do that by funding more high-quality research and trials, to get treatments out of the lab and into patients as soon as possible,” he added.


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs